Based on research at Grousbeck Gene Therapy Center and Massachusetts Eye and Ear, Affinia has raised $60m in a series A round to advance its gene therapies into the clinic.
Affinia Therapeutics, a US-based gene therapy developer based on foundational research at Grousbeck Gene Therapy Center, completed a $60m series A round on Tuesday featuring biotechnology and chemicals producer Lonza Group and care provider Partners Healthcare’s Partners Innovation Fund.
The round was co-led by F-Prime Capital, a subsidiary of investment and financial services group Fidelity, and venture capital firm New Enterprise Associates, and included Atlas Venture and Alexandria Venture Investments, the VC arm of real estate investment trust Alexandria…
